PT750509E - Utilizacao de il-12 e antagonistas de il-12 para o fabrico de uma composicao farmaceutica para o tratamento de doencas auto-imunes - Google Patents
Utilizacao de il-12 e antagonistas de il-12 para o fabrico de uma composicao farmaceutica para o tratamento de doencas auto-imunesInfo
- Publication number
- PT750509E PT750509E PT95912666T PT95912666T PT750509E PT 750509 E PT750509 E PT 750509E PT 95912666 T PT95912666 T PT 95912666T PT 95912666 T PT95912666 T PT 95912666T PT 750509 E PT750509 E PT 750509E
- Authority
- PT
- Portugal
- Prior art keywords
- autoimmune
- antagonists
- auto
- treatment
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21262994A | 1994-03-14 | 1994-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT750509E true PT750509E (pt) | 2002-08-30 |
Family
ID=22791827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT95912666T PT750509E (pt) | 1994-03-14 | 1995-03-07 | Utilizacao de il-12 e antagonistas de il-12 para o fabrico de uma composicao farmaceutica para o tratamento de doencas auto-imunes |
Country Status (14)
Country | Link |
---|---|
US (1) | US6338848B1 (pt) |
EP (4) | EP1179348A3 (pt) |
JP (1) | JP3798426B2 (pt) |
AT (1) | ATE217533T1 (pt) |
AU (1) | AU689236B2 (pt) |
CA (1) | CA2185565C (pt) |
DE (1) | DE69526728T3 (pt) |
DK (1) | DK0750509T4 (pt) |
ES (1) | ES2173953T5 (pt) |
IL (1) | IL112677A (pt) |
PT (1) | PT750509E (pt) |
TW (1) | TW400233B (pt) |
WO (1) | WO1995024918A1 (pt) |
ZA (1) | ZA95960B (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
US6830751B1 (en) * | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US20010055581A1 (en) * | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
ATE256476T1 (de) * | 1996-11-15 | 2004-01-15 | Kennedy Inst Of Rheumatology | Unterdrückung von tnfalpha und il-12 in der therapie |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US7026456B1 (en) | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
TR200002145T2 (tr) * | 1998-01-23 | 2000-11-21 | F.Hoffmann-La Roche Ag | İnsan IL-12'ye karşı antikorlar |
DE69927520T2 (de) * | 1998-12-09 | 2006-06-22 | Protein Design Labs, Inc., Fremont | Verwendung von il-12 antikörpern zur behandlung von psoriasis |
WO2000047558A1 (fr) | 1999-02-10 | 2000-08-17 | Welfide Corporation | Composes amide et leur utilisation medicinale |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
KR101222450B1 (ko) * | 1999-03-25 | 2013-01-16 | 애보트 게엠베하 운트 콤파니 카게 | 사람 il-12에 결합하는 사람 항체 및 이의 제조방법 |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
AU2005200515B2 (en) * | 1999-03-25 | 2006-07-13 | AbbVie Deutschland GmbH & Co. KG | Human antibodies that bind human IL-12 and methods for producing |
JP4676049B2 (ja) * | 1999-07-21 | 2011-04-27 | 生化学工業株式会社 | Il−12産生抑制剤 |
US6346247B1 (en) * | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
WO2003083071A2 (en) * | 2002-03-26 | 2003-10-09 | Centocor, Inc. | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
EP1694301A4 (en) | 2003-12-02 | 2009-11-18 | Cytimmune Sciences Inc | METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES |
GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
US20070178520A1 (en) * | 2004-02-27 | 2007-08-02 | Barbara Wolff-Winiski | Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors |
US20060024725A1 (en) | 2004-07-30 | 2006-02-02 | Robert Hussa | Oncofetal fibronectin as a marker for pregnancy-related indications |
KR20070094927A (ko) | 2004-12-21 | 2007-09-27 | 센토코 인코포레이티드 | 항-il-12 항체, 에피토프, 조성물, 방법 및 용도 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
EP2500356A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
NZ578065A (en) | 2007-01-16 | 2012-09-28 | Abbott Lab | Methods for treating psoriasis with an antibody which binds to an epitope |
NZ598881A (en) | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
NZ587765A (en) | 2008-03-18 | 2013-02-22 | Abbott Lab | Methods for treating psoriasis |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
RU2011104348A (ru) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
BRPI0919511A2 (pt) * | 2008-09-30 | 2015-12-08 | Baylor Res Inst | métodos de redução de células t auxiliares de células b para o tratamento de doenças autoimunes |
WO2010062896A1 (en) * | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
KR20140048229A (ko) | 2009-09-14 | 2014-04-23 | 애브비 인코포레이티드 | 건선을 치료하는 방법 |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2812310A1 (en) * | 2010-09-28 | 2012-04-19 | Neumedicines, Inc. | Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration |
KR20130133247A (ko) | 2010-12-21 | 2013-12-06 | 애브비 인코포레이티드 | Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도 |
DK2709651T3 (en) * | 2011-05-19 | 2018-01-08 | Univ Rush Medical Center | IL-12-P40 MONOMER, MONOCLONAL ANTIBODY AGAINST P40 HOMODIMER, AND A COMBINATION OF THE TWO FOR THE TREATMENT OF AUTO-IMMUNE DISEASE |
WO2013016634A1 (en) * | 2011-07-27 | 2013-01-31 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
CA2890263C (en) | 2012-11-01 | 2020-03-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
US11578124B2 (en) | 2018-05-18 | 2023-02-14 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-IL12/IL23 antibody |
DK3883606T5 (da) | 2018-09-24 | 2024-01-02 | Janssen Biotech Inc | Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof |
JP2022534020A (ja) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク,インコーポレーテツド | Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
ATE369383T1 (de) * | 1989-12-22 | 2007-08-15 | Hoffmann La Roche | Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor |
GB9207732D0 (en) * | 1992-04-06 | 1992-05-27 | Isis Innovation | Wound repair |
DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
EP0638644A1 (en) * | 1993-07-19 | 1995-02-15 | F. Hoffmann-La Roche Ag | Receptors of interleukin-12 and antibodies |
US5536657A (en) * | 1993-07-19 | 1996-07-16 | Hoffmann-La Roche Inc. | Recombinant DNA encoding human receptor for interleukin-12 |
US5853721A (en) * | 1995-01-31 | 1998-12-29 | Hoffmann-La Roche Inc. | Antibody to interleukin-12 receptor |
RU2270030C2 (ru) * | 1996-02-09 | 2006-02-20 | Абботт Байотекнолоджи эЛтиди. | СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
PL336464A1 (en) * | 1997-03-18 | 2000-06-19 | Basf Ag | Method of and compositions for modulating reactivity in respect to corticosteroids i |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
TR200002145T2 (tr) * | 1998-01-23 | 2000-11-21 | F.Hoffmann-La Roche Ag | İnsan IL-12'ye karşı antikorlar |
US8700033B2 (en) | 2008-08-22 | 2014-04-15 | International Business Machines Corporation | Dynamic access to radio networks |
CN102377479B (zh) | 2010-08-11 | 2015-01-21 | 华为技术有限公司 | 数据同步方法及系统、光网络单元 |
-
1995
- 1995-02-07 ZA ZA95960A patent/ZA95960B/xx unknown
- 1995-02-14 TW TW084101380A patent/TW400233B/zh not_active IP Right Cessation
- 1995-02-16 IL IL11267795A patent/IL112677A/xx not_active IP Right Cessation
- 1995-03-07 WO PCT/US1995/002550 patent/WO1995024918A1/en active IP Right Grant
- 1995-03-07 PT PT95912666T patent/PT750509E/pt unknown
- 1995-03-07 CA CA002185565A patent/CA2185565C/en not_active Expired - Lifetime
- 1995-03-07 EP EP01117762A patent/EP1179348A3/en not_active Withdrawn
- 1995-03-07 AT AT95912666T patent/ATE217533T1/de active
- 1995-03-07 ES ES95912666T patent/ES2173953T5/es not_active Expired - Lifetime
- 1995-03-07 DE DE69526728T patent/DE69526728T3/de not_active Expired - Lifetime
- 1995-03-07 AU AU19749/95A patent/AU689236B2/en not_active Expired
- 1995-03-07 EP EP10156687A patent/EP2201959A3/en not_active Withdrawn
- 1995-03-07 EP EP10184543A patent/EP2311484A1/en not_active Withdrawn
- 1995-03-07 JP JP52404495A patent/JP3798426B2/ja not_active Expired - Lifetime
- 1995-03-07 DK DK95912666T patent/DK0750509T4/da active
- 1995-03-07 EP EP95912666A patent/EP0750509B2/en not_active Expired - Lifetime
-
2000
- 2000-02-25 US US09/513,380 patent/US6338848B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK0750509T4 (da) | 2006-10-16 |
EP0750509B1 (en) | 2002-05-15 |
DE69526728T3 (de) | 2007-01-04 |
EP1179348A3 (en) | 2003-12-03 |
ES2173953T5 (es) | 2007-03-01 |
EP2311484A1 (en) | 2011-04-20 |
DE69526728T2 (de) | 2002-11-21 |
ATE217533T1 (de) | 2002-06-15 |
DK0750509T3 (da) | 2002-07-08 |
US6338848B1 (en) | 2002-01-15 |
DE69526728D1 (de) | 2002-06-20 |
ZA95960B (en) | 1995-10-10 |
WO1995024918A1 (en) | 1995-09-21 |
EP1179348A2 (en) | 2002-02-13 |
EP0750509A1 (en) | 1997-01-02 |
JP3798426B2 (ja) | 2006-07-19 |
EP2201959A3 (en) | 2011-03-16 |
IL112677A0 (en) | 1995-05-26 |
CA2185565A1 (en) | 1995-09-21 |
EP0750509B2 (en) | 2006-06-14 |
CA2185565C (en) | 2009-02-03 |
ES2173953T3 (es) | 2002-11-01 |
AU689236B2 (en) | 1998-03-26 |
AU1974995A (en) | 1995-10-03 |
IL112677A (en) | 2000-01-31 |
EP2201959A2 (en) | 2010-06-30 |
JPH09510444A (ja) | 1997-10-21 |
TW400233B (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT750509E (pt) | Utilizacao de il-12 e antagonistas de il-12 para o fabrico de uma composicao farmaceutica para o tratamento de doencas auto-imunes | |
Saxne et al. | Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis | |
Viller et al. | Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. | |
Sakkas et al. | Interleukin-12 is expressed by infiltrating macrophages and synovial lining cells in rheumatoid arthritis and osteoarthritis | |
BR9106977A (pt) | Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero | |
DK0692970T3 (da) | Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli | |
AU2840789A (en) | Continuous release pharmaceutical compositions | |
DK0754048T3 (da) | Behandling af partielt væksthormon-insentivitetssyndrom | |
DE69024369T2 (de) | Latenz assoziierte peptide und deren verwendung | |
DK399288D0 (da) | Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion | |
DK0482089T3 (da) | Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker | |
BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
Husted et al. | The influence of age on the response to anticoagulants. | |
HUT59600A (en) | Process for producing pharmaceutical compositions containing 5-methyl-isoxazoe-4-carboxylik-anilides or alpha-/2-hydroxy-ethylidene/-alpha-cyano-acetic-anilides for treating eye-diseases | |
ES2006722T3 (es) | Metodo para el tratamiento de enfermedades degenerativas de las articulaciones. | |
DE69528168D1 (de) | Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes | |
BR0115527A (pt) | Análogos de ácido graxo para o tratamento de distúrbios imflamatórios e autoimunes | |
Hogan | Inflammation and its effect on the vitreous. | |
KR910009255A (ko) | 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체 | |
Neistadt et al. | A program for sex counseling the physically disabled. | |
Reynolds | Drugs in Blood and Brain: The Value of Serum Diphenylhydantoin (Phenytoin) Levels in the Management of Epilepsy | |
Aubert et al. | Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia | |
Finnerty-Fried | Adapting rehabilitation counseling for older persons. | |
Gegout et al. | Accelerated communication assay of circulating hyaluronic acid in the rat: Study of diurnal variation and effect of anesthesia | |
Hennekes et al. | Strategies for targeting IL-4 as a novel therapeutic approach for the treatment of atopic dermatitis |